Interleukin-23 (IL-23) and tumor necrosis factor α (TNF-α) play pivotal roles in psoriasis, and their corresponding inhibitors are recommended for first-line treatment of moderate to severe plaque psoriasis by the American Academy of Dermatology-National Psoriasis Foundation guidelines (2). This evidence concerns the gene IL37 and psoriasis vulgaris.